CA2699504C - Tetrahydroquinoline derivatives for treating post-traumatic stress disorders - Google Patents

Tetrahydroquinoline derivatives for treating post-traumatic stress disorders Download PDF

Info

Publication number
CA2699504C
CA2699504C CA2699504A CA2699504A CA2699504C CA 2699504 C CA2699504 C CA 2699504C CA 2699504 A CA2699504 A CA 2699504A CA 2699504 A CA2699504 A CA 2699504A CA 2699504 C CA2699504 C CA 2699504C
Authority
CA
Canada
Prior art keywords
formula
pharmaceutically acceptable
phenyl
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2699504A
Other languages
English (en)
French (fr)
Other versions
CA2699504A1 (en
Inventor
Francois Jenck
Original Assignee
Actelion Pharmaceuticals Ltd
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40467356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2699504(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CA2699504A1 publication Critical patent/CA2699504A1/en
Application granted granted Critical
Publication of CA2699504C publication Critical patent/CA2699504C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2699504A 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders Active CA2699504C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IBPCT/IB2007/054130 2007-10-10
IB2007054130 2007-10-10
PCT/IB2008/054138 WO2009047723A2 (en) 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders

Publications (2)

Publication Number Publication Date
CA2699504A1 CA2699504A1 (en) 2009-04-16
CA2699504C true CA2699504C (en) 2015-11-24

Family

ID=40467356

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2699504A Active CA2699504C (en) 2007-10-10 2008-10-09 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders

Country Status (27)

Country Link
US (1) US9532985B2 (enExample)
EP (1) EP2207550B1 (enExample)
JP (1) JP5883222B2 (enExample)
KR (1) KR101733247B1 (enExample)
CN (1) CN101820878B (enExample)
AR (1) AR068768A1 (enExample)
AU (1) AU2008309194B2 (enExample)
BR (1) BRPI0818617A2 (enExample)
CA (1) CA2699504C (enExample)
CY (1) CY1114799T1 (enExample)
DK (1) DK2207550T3 (enExample)
EA (1) EA017443B1 (enExample)
ES (1) ES2444418T3 (enExample)
HR (1) HRP20140214T1 (enExample)
IL (1) IL204838A (enExample)
MA (1) MA31800B1 (enExample)
MX (1) MX2010003711A (enExample)
MY (1) MY153044A (enExample)
NZ (1) NZ585086A (enExample)
PE (1) PE20091010A1 (enExample)
PL (1) PL2207550T3 (enExample)
PT (1) PT2207550E (enExample)
SI (1) SI2207550T1 (enExample)
TW (1) TWI428129B (enExample)
UA (1) UA99150C2 (enExample)
WO (1) WO2009047723A2 (enExample)
ZA (1) ZA201003251B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2669561A1 (en) 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives
KR20110036069A (ko) 2008-06-25 2011-04-06 액테리온 파마슈티칼 리미티드 5,6,7,8-테트라히드로-이미다조[1,5-ａ]피라진 화합물
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist
KR101802726B1 (ko) 2010-08-24 2017-11-29 액테리온 파마슈티칼 리미티드 오렉신 수용체 안타고니스트로서의 프롤린 술폰아미드 유도체
MY160969A (en) 2010-09-22 2017-03-31 Eisai R&D Man Co Ltd Cyclopropane compounds
CA2815179A1 (en) 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
WO2012085857A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides
CN103380130B (zh) 2011-02-18 2015-06-17 埃科特莱茵药品有限公司 用作为食欲素拮抗剂的新颖的吡唑和咪唑衍生物
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
EA024106B1 (ru) 2011-11-08 2016-08-31 Актелион Фармасьютиклз Лтд. Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
PT2855453T (pt) 2012-06-04 2017-03-09 Actelion Pharmaceuticals Ltd Derivados de benzimidazol-prolina
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
EP2970241A1 (en) 2013-03-12 2016-01-20 Actelion Pharmaceuticals Ltd. Azetidine amide derivatives as orexin receptor antagonists
PL3077389T3 (pl) 2013-12-03 2018-03-30 Idorsia Pharmaceuticals Ltd KRYSTALICZNA POSTAĆ (S)-(2-(6-CHLORO-7-METYLO-1H-BENZO[D]lMIDAZOL-2-ILO)- 2-METYLOPIROLIDYN-1-YLO)(5-METOKSY-2-(2H-1,2,3-TRIAZOL-2-ILO)FENYLO)METANONU I JEJ ZASTOSOWANIE JAKO ANTAGONISTY RECEPTORA OREKSYNY
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
UA116053C2 (uk) 2013-12-04 2018-01-25 Ідорсія Фармасьютікалз Лтд Застосування похідних бензоімідазолу-проліну
MX376164B (es) 2014-10-23 2025-03-07 Eisai R&D Man Co Ltd Composiciones y metodos para tratar el insomnio.
WO2019024845A1 (zh) * 2017-08-01 2019-02-07 苏州科睿思制药有限公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020007977A1 (en) 2018-07-06 2020-01-09 Idorsia Pharmaceuticals Ltd 7-trifluoromethyl-[1,4]diazepan derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
TW202400149A (zh) 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001260113B2 (en) * 2000-03-14 2006-04-06 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivatives
KR20050114242A (ko) 2003-03-26 2005-12-05 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서 이용되는테트라하이드로이소퀴놀릴 아세트아마이드 유도체
US7763638B2 (en) * 2004-03-01 2010-07-27 Actelion Pharmaceuticals Ltd. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
US7501395B2 (en) * 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
CA2644010A1 (en) * 2006-03-15 2007-09-20 Actelion Pharmaceuticals Ltd Tetrahydroisoquinoline derivatives to enhance memory function
EP2402322A1 (en) 2010-07-02 2012-01-04 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist

Also Published As

Publication number Publication date
HK1145440A1 (en) 2011-04-21
IL204838A0 (en) 2010-11-30
EP2207550B1 (en) 2013-12-11
JP2011500550A (ja) 2011-01-06
EA201000557A1 (ru) 2010-10-29
NZ585086A (en) 2012-03-30
BRPI0818617A2 (pt) 2015-04-07
PT2207550E (pt) 2014-02-07
EA017443B1 (ru) 2012-12-28
WO2009047723A2 (en) 2009-04-16
AU2008309194B2 (en) 2013-10-03
MA31800B1 (fr) 2010-10-01
ES2444418T3 (es) 2014-02-25
TW200932231A (en) 2009-08-01
DK2207550T3 (da) 2014-01-27
KR101733247B1 (ko) 2017-05-08
UA99150C2 (ru) 2012-07-25
CN101820878A (zh) 2010-09-01
MY153044A (en) 2014-12-31
CA2699504A1 (en) 2009-04-16
WO2009047723A3 (en) 2009-05-28
PL2207550T3 (pl) 2014-05-30
SI2207550T1 (sl) 2014-03-31
IL204838A (en) 2014-09-30
CN101820878B (zh) 2012-02-01
HRP20140214T1 (hr) 2014-04-11
AU2008309194A1 (en) 2009-04-16
US9532985B2 (en) 2017-01-03
TWI428129B (zh) 2014-03-01
PE20091010A1 (es) 2009-08-08
CY1114799T1 (el) 2016-12-14
ZA201003251B (en) 2011-07-27
EP2207550A2 (en) 2010-07-21
JP5883222B2 (ja) 2016-03-09
US20100234420A1 (en) 2010-09-16
KR20100065203A (ko) 2010-06-15
MX2010003711A (es) 2010-04-30
AR068768A1 (es) 2009-12-02

Similar Documents

Publication Publication Date Title
CA2699504C (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
AU2011215870B2 (en) Methods and compositions for improving cognitive function
WO2009058261A1 (en) Modulation of sleep with nr2b receptor antagonists
KR20100016270A (ko) 비맥각계의 선택적 ｄ2 수용체 작용제를 유효 성분으로서 함유하는 후안부 질환의 예방 또는 치료제
JP2010531810A (ja) 点眼投与による神経疾患または精神神経疾患の治療または予防
MXPA00013033A (es) Sulfonamidas que contienen isoesteres n-heterociclicos para las enfermedades de la vision y la memoria.
WO2004035000A2 (en) Enhancement of sleep with t-type calcium channel antagonists
EP1113797A4 (en) TREATMENT OF PERSISTENT PAIN
JP2008542417A (ja) 進行性ミオクローヌスてんかんに特徴付けられる疾患の治療用ブリバラセタムの使用
IL262920A (en) A triangular combination of pure 5 – ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor agonists
HK1145440B (en) Tetrahydroquinoline derivatives for treating post-traumatic stress disorders
JP2007519733A (ja) アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
KR980008226A (ko) 시각기능장애의 예방 및 치료제
WO2005023256A1 (en) Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
ZA200308020B (en) Pharmaceutically active compounds and methods of use
CN1499974A (zh) 伴有前列腺肥大症的膀胱刺激症状治疗药
Sévoz-Couche et al. Antinociceptive effect of cardiopulmonary chemoreceptor and baroreceptor reflex activation in the rat
MXPA00013031A (es) Ureas y carbamatos de acidos carboxilicos n-heterociclicos e isoesteres, para las enfermedades de la vision y la memoria.
JP2014525474A (ja) 光過敏性てんかんの予防または治療における使用のための１ｈ−キナゾリン−２，４−ジオンの使用
Alkozi et al. Improving melatonin delivery within the eye
CA3018375C (en) Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages
WO2017059486A1 (en) Compositions and methods for the treatment of epilepsy
CN106309436A (zh) 可用作乙酰胆碱酯酶抑制剂的色胺衍生物及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130916